Denis Krude
President & CEO
Denis Krude leads deutraMed® in fulfilling its mission to develop, produce and deliver value-added deuterium-containing products to global customers. With responsibility for the overall direction and performance of the organization, he applies over two decades of executive-level experience in engineering and technology businesses to the role. Denis has a proven track record of driving innovation, navigating complex challenges, and delivering results that exceed expectations. He brings more than 25 years of experience heading multicultural and cross-functional teams across multiple locations worldwide, emphasizing performance and leadership values. Denis has led numerous international large-scale plant engineering and EPC (Engineering, Procurement and Construction) projects in various functions, with expertise that spans the entire plant engineering value chain: business development, sales, product management, engineering, project execution and after-sales service. Before joining deutraMed®, Denis served as CEO and a Member of the Executive Board at a leading technology and plant engineering company in Germany that specializes in electrolysis and green hydrogen. Denis, a German national, holds a Master’s Degree in Electrical Engineering and Information Technology from RWTH Aachen University.
Markus Richter
Chief Financial Officer
Markus Richter leads the development and implementation of deutraMed’s financial operations and strategy. He is responsible for the company’s financial planning and reporting, and leads its equity and debt financing initiatives. Markus is an international finance expert with senior-level experience a number of companies, including one where he served as Head of Structured Finance for Europe, the Middle East, Asia and Africa. He is a global debt and equity expert with a proven record in equity, buyer’s credits, working capital and other financing. His experience includes the development of start-ups in renewable and non-renewable power generation and process technologies, as well as supply chain finance, mergers and acquisitions, and project development.
Lorraine Mickiewicz
Chief Operating Officer
Lorraine Mickiewicz heads deutraMed’s human resources function, oversees corporate governance, and has a leadership role in business operations and finance. Her operations role includes logistics and regulatory approvals for the advanced deuterium-based products sold by deutraMed® to customers around the world. Prior to joining the company, Lorraine gained customer sales and service experience at a leading insurance provider.
Sales & Business Development
A. James Farmilo, B.Sc. (Hons.), M.Sc. (Hons.), Ph.D.
Vice President
Dr. James Farmilo is a scientist and team leader who is focused on business development as well as the development and production of deuterated products. A skilled inventor and creative thinker, he has 35 years of experience in the development and commercialization of advanced technologies. Dr. Farmilo has started, developed and sold numerous businesses in the medical research and medical diagnostic fields. He sold one of these businesses to another company, which he joined in 1994 and was responsible for its global business activities in microbiology, clinical immunochemistry and OEM. He also led R&D teams, creating alliances with major drug and diagnostic companies to develop and bring new products to market. Dr. Farmilo holds a B.Sc. (Hons.) in Math and Physics from the University of Alberta, and an M.Sc. (Hons.) and Ph.D. in Medical Biophysics from the University of Toronto.
Steve Bovair
Sales Manager
Steve Bovair leads deutraMed’s sales team. He applies extensive experience in the supply and shipment of deuterium gas and other deuterated products to support his global customers’ success. Steve serves customers in semiconductor fabrication and other advanced technologies to meet their exacting specifications. Before joining deutraMed®, he worked for 25 years in the information technology industry in technical sales and product management. Steve also operated his own business for several years.
Quality/Science
Dr. Pavel Gris
PhD, FRSC, C. Chem – Chief Scientist
Dr. Gris leads deutraMed’s scientific and analytic activities. His main focus is the development and manufacturing of deuterated precursors for the pharmaceutical industry as well as deuterated intermediates for the electronics industry. Dr. Gris also studies efficient and innovative ways of synthesizing deuterated intermediates and precursors. Dr. Gris joined deutraMed® in 2018 after a career in academia where he gained extensive experience in a broad range of sciences, research and university-level teaching at Western University, Concordia University, McGill University and University of North Carolina at Chapel Hill. He earned a Ph.D. at Western University in London, Canada, and has completed consecutive post-doctoral appointments at the University of North Carolina at Chapel Hill and McGill University in Montreal. Dr. Gris is a Fellow of the Royal Society of Chemistry and a Chartered Chemist in the Province of Ontario.
Our Talent
deutraMed’s forward-thinking company culture of learning and discovery draws world-leading talent and empowers our team to innovate, perform, and stretch boundaries. Our entrepreneurial spirit and dedication to innovation and excellence drives everything we do at deutraMed®. Through the passionate support of our employees and leading in-house expertise, we deliver deuterium innovations that foster a healthier and connected world.
Join Our Team
deutraMed® is a fast-growing company and is constantly looking for top talent to join our team. We are always interested in learning of driven individuals who are interested in working with us to create a healthier and more connected world. If you believe your future lies in deuterium and it’s positive impact on the world, reach out to us.